Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies.

Darvishian M, Wong S, Binka M, Yu A, Ramji A, Yoshida EM, Wong J, Rossi C, Butt ZA, Bartlett S, Pearce ME, Samji H, Cook D, Alvarez M, Chong M, Tyndall M, Krajden M, Janjua NZ.

J Viral Hepat. 2019 Oct 30. doi: 10.1111/jvh.13228. [Epub ahead of print]

PMID:
31664755
2.

Epidemiologic and clinical features of chronic hepatitis B virus infection in 8 Canadian provinces: a descriptive study by the Canadian HBV Network.

Coffin CS, Ramji A, Cooper CL, Miles D, Doucette KE, Wong P, Tam E, Wong DK, Wong A, Ukabam S, Bailey RJ, Tsoi K, Conway B, Barrett L, Michalak TI, Congly SE, Minuk G, Kaita K, Kelly E, Ko HH, Janssen HLA, Uhanova J, Lethebe BC, Haylock-Jacobs S, Ma MM, Osiowy C, Fung SK; Canadian HBV Network.

CMAJ Open. 2019 Oct 22;7(4):E610-E617. doi: 10.9778/cmajo.20190103. Print 2019 Oct-Dec. Erratum in: CMAJ Open. 2019 Dec 3;7(4):E699.

3.

Crossing the Cervicothoracic Junction in Cervical Arthrodesis Results in Lower Rates of Adjacent Segment Disease Without Affecting Operative Risks or Patient-Reported Outcomes.

Ibaseta A, Rahman R, Andrade NS, Uzosike AC, Byrapogu VK, Ramji AF, Skolasky RL, Reidler JS, Kebaish KM, Riley LH 3rd, Sciubba DM, Cohen DB, Neuman BJ.

Clin Spine Surg. 2019 Nov;32(9):377-381. doi: 10.1097/BSD.0000000000000897.

PMID:
31609799
4.

Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy.

Janjua NZ, Darvishian M, Wong S, Yu A, Rossi C, Ramji A, Yoshida EM, Butt ZA, Samji H, Chong M, Chapinal N, Cook D, Alvarez M, Tyndall M, Krajden M; British Columbia Hepatitis Testers Cohort Team.

Hepatol Commun. 2019 Jan 10;3(4):478-492. doi: 10.1002/hep4.1307. eCollection 2019 Apr.

5.

Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C).

Poordad F, Shiffman ML, Ghesquiere W, Wong A, Huhn GD, Wong F, Ramji A, Shafran SD, McPhee F, Yang R, Noviello S, Linaberry M; ALLY-3C study team.

Antivir Ther. 2019;24(1):35-44. doi: 10.3851/IMP3278.

PMID:
30382942
6.

Corrigendum to "NXP-2 Positive Dermatomyositis: A Unique Clinical Presentation".

Butt Z, Patel L, Das MK, Mecoli CA, Ramji A.

Case Rep Rheumatol. 2018 Sep 9;2018:1041738. doi: 10.1155/2018/1041738. eCollection 2018.

7.

Platelet-Rich Plasma: Review of Current Literature on its Use for Tendon and Ligament Pathology.

Kia C, Baldino J, Bell R, Ramji A, Uyeki C, Mazzocca A.

Curr Rev Musculoskelet Med. 2018 Dec;11(4):566-572. doi: 10.1007/s12178-018-9515-y. Review.

8.

Estimating the impact of early hepatitis C virus clearance on hepatocellular carcinoma risk.

Darvishian M, Janjua NZ, Chong M, Cook D, Samji H, Butt ZA, Yu A, Alvarez M, Yoshida E, Ramji A, Wong J, Woods R, Tyndall M, Krajden M.

J Viral Hepat. 2018 Dec;25(12):1481-1492. doi: 10.1111/jvh.12977. Epub 2018 Aug 28.

PMID:
30047609
9.

Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV Infection.

Seto WK, Asahina Y, Brown TT, Peng CY, Stanciu C, Abdurakhmanov D, Tabak F, Nguyen TT, Chuang WL, Inokuma T, Ikeda F, Santantonio TA, Habersetzer F, Ramji A, Lau AH, Suri V, Flaherty JF, Wang H, Gaggar A, Subramanian GM, Mukewar S, Brunetto MR, Fung S, Chan HL.

Clin Gastroenterol Hepatol. 2018 Jun 20. pii: S1542-3565(18)30633-5. doi: 10.1016/j.cgh.2018.06.023. [Epub ahead of print]

PMID:
29933096
10.

The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver.

Shah H, Bilodeau M, Burak KW, Cooper C, Klein M, Ramji A, Smyth D, Feld JJ; Canadian Association for the Study of the Liver.

CMAJ. 2018 Jun 4;190(22):E677-E687. doi: 10.1503/cmaj.170453. No abstract available.

11.

NXP-2 Positive Dermatomyositis: A Unique Clinical Presentation.

Butt Z, Patel L, Das MK, Mecoli CA, Ramji A.

Case Rep Rheumatol. 2017;2017:4817275. doi: 10.1155/2017/4817275. Epub 2017 Jun 13. Erratum in: Case Rep Rheumatol. 2018 Sep 9;2018:1041738.

12.

Hepatitis C testing in Canada: don't leave baby boomers behind.

Ti L, Lima V, Hull M, Nosyk B, Joy J, Montaner J, Krajden M, Harrigan R, Kerr T, Shannon K, Wood E, Shoveller J, Ramji A, Ko HH, Yoshida E, Hall D, Barrios R.

CMAJ. 2017 Jun 26;189(25):E870-E871. doi: 10.1503/cmaj.733111. No abstract available.

13.

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.

Bourlière M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling JM, Tran TT, Pianko S, Bansal MB, de Lédinghen V, Hyland RH, Stamm LM, Dvory-Sobol H, Svarovskaia E, Zhang J, Huang KC, Subramanian GM, Brainard DM, McHutchison JG, Verna EC, Buggisch P, Landis CS, Younes ZH, Curry MP, Strasser SI, Schiff ER, Reddy KR, Manns MP, Kowdley KV, Zeuzem S; POLARIS-1 and POLARIS-4 Investigators.

N Engl J Med. 2017 Jun 1;376(22):2134-2146. doi: 10.1056/NEJMoa1613512.

14.

Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.

Feld JJ, Ramji A, Shafran SD, Willems B, Marotta P, Huchet E, Vachon ML, Svarovskaia ES, Huang KC, Hyland RH, Yun C, Massetto B, Brainard DM, McHutchison JG, Tam E, Bailey R, Cooper C, Yoshida EM, Greenbloom S, Elkhashab M, Borgia S, Swain MG.

Clin Infect Dis. 2017 Jul 1;65(1):13-19. doi: 10.1093/cid/cix289.

PMID:
28535298
15.

Chronic Hepatitis with Liver Granulomas in a Patient with Granuloma Annulare: A Case Report and Review of the Literature.

Alsahafi M, AlJasser MI, Kalia S, Yang HM, Ramji A.

Case Rep Gastrointest Med. 2017;2017:8768529. doi: 10.1155/2017/8768529. Epub 2017 Feb 23.

16.

Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study.

Janjua NZ, Islam N, Wong J, Yoshida EM, Ramji A, Samji H, Butt ZA, Chong M, Cook D, Alvarez M, Darvishian M, Tyndall M, Krajden M.

J Viral Hepat. 2017 Aug;24(8):624-630. doi: 10.1111/jvh.12684. Epub 2017 Feb 20.

PMID:
28130810
17.

The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC).

Janjua NZ, Kuo M, Yu A, Alvarez M, Wong S, Cook D, Wong J, Grebely J, Butt ZA, Samji H, Ramji A, Tyndall M, Krajden M.

EBioMedicine. 2016 Oct;12:189-195. doi: 10.1016/j.ebiom.2016.08.035. Epub 2016 Aug 25.

18.

Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.

Maan R, van Tilborg M, Deterding K, Ramji A, van der Meer AJ, Wong F, Fung S, Sherman M, Manns MP, Cornberg M, Hansen BE, Wedemeyer H, Janssen HL, de Knegt RJ, Feld JJ.

Clin Gastroenterol Hepatol. 2016 Dec;14(12):1821-1830.e6. doi: 10.1016/j.cgh.2016.07.001. Epub 2016 Jul 9.

PMID:
27404965
19.

Effect of a "pill mill" law on opioid prescribing and utilization: The case of Texas.

Lyapustina T, Rutkow L, Chang HY, Daubresse M, Ramji AF, Faul M, Stuart EA, Alexander GC.

Drug Alcohol Depend. 2016 Feb 1;159:190-7. doi: 10.1016/j.drugalcdep.2015.12.025. Epub 2015 Dec 31.

20.

Low Prevalence of Anterior and Posterior Cruciate Ligament Injuries in Patients With Achondroplasia.

Brooks JT, Ramji AF, Lyapustina TA, Yost MT, Ain MC.

J Pediatr Orthop. 2017 Jan;37(1):e43-e47.

PMID:
26469688
21.

Epidermal Growth Factor Receptor Expression in Triple Negative and Nontriple Negative Breast Carcinomas.

Changavi AA, Shashikala A, Ramji AS.

J Lab Physicians. 2015 Jul-Dec;7(2):79-83. doi: 10.4103/0974-2727.163129.

22.

Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial.

Lagging M, Brown A, Mantry PS, Ramji A, Weilert F, Vierling JM, Howe A, Gendrano IN 3rd, Hwang P, Zhang B, Wahl J, Robertson M, Mobashery N.

J Viral Hepat. 2016 Feb;23(2):80-8. doi: 10.1111/jvh.12464. Epub 2015 Sep 10.

PMID:
26353843
23.

Cannulated Lag Screw Fixation of Displaced Lateral Humeral Condyle Fractures Is Associated With Lower Rates of Open Reduction and Infection Than Pin Fixation.

Stein BE, Ramji AF, Hassanzadeh H, Wohlgemut JM, Ain MC, Sponseller PD.

J Pediatr Orthop. 2017 Jan;37(1):7-13.

PMID:
26192878
24.

Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.

Muir AJ, Poordad F, Lalezari J, Everson G, Dore GJ, Herring R, Sheikh A, Kwo P, Hézode C, Pockros PJ, Tran A, Yozviak J, Reau N, Ramji A, Stuart K, Thompson AJ, Vierling J, Freilich B, Cooper J, Ghesquiere W, Yang R, McPhee F, Hughes EA, Swenson ES, Yin PD.

JAMA. 2015 May 5;313(17):1736-44. doi: 10.1001/jama.2015.3868.

25.

Rate, delay and predictors of hepatitis C treatment in British Columbia.

Yau AH, Lee T, Ramji A, Ko HH.

Can J Gastroenterol Hepatol. 2015 Aug-Sep;29(6):315-20. Epub 2015 Apr 15.

26.

Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.

Dore GJ, Lawitz E, Hézode C, Shafran SD, Ramji A, Tatum HA, Taliani G, Tran A, Brunetto MR, Zaltron S, Strasser SI, Weis N, Ghesquiere W, Lee SS, Larrey D, Pol S, Harley H, George J, Fung SK, de Lédinghen V, Hagens P, McPhee F, Hernandez D, Cohen D, Cooney E, Noviello S, Hughes EA.

Gastroenterology. 2015 Feb;148(2):355-366.e1. doi: 10.1053/j.gastro.2014.10.007. Epub 2014 Oct 13.

PMID:
25311593
27.

Burden of disease and cost of chronic hepatitis C infection in Canada.

Myers RP, Krajden M, Bilodeau M, Kaita K, Marotta P, Peltekian K, Ramji A, Estes C, Razavi H, Sherman M.

Can J Gastroenterol Hepatol. 2014 May;28(5):243-50. Review.

28.

Strategies to manage hepatitis C virus (HCV) disease burden.

Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, Örmeci N, Van Vlierberghe H, Gschwantler M, Akarca U, Aleman S, Balık I, Berg T, Bihl F, Bilodeau M, Blasco AJ, Brandão Mello CE, Bruggmann P, Calinas F, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cornberg M, Cramp ME, Dore GJ, Doss W, El-Sayed MH, Ergör G, Estes C, Falconer K, Félix J, Ferraz ML, Ferreira PR, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL Jr, Guimarães Pessôa M, Hézode C, Hindman SJ, Hofer H, Husa P, Idilman R, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Lázaro P, Marinho RT, Marotta P, Mauss S, Mendes Correa MC, Moreno C, Müllhaupt B, Myers RP, Nemecek V, Øvrehus AL, Parkes J, Peltekian KM, Ramji A, Razavi H, Reis N, Roberts SK, Roudot-Thoraval F, Ryder SD, Sarmento-Castro R, Sarrazin C, Semela D, Sherman M, Shiha GE, Sperl J, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, Van Damme P, van Thiel I, Vandijck D, Vogel W, Waked I, Weis N, Wiegand J, Yosry A, Zekry A, Negro F, Sievert W, Gower E.

J Viral Hepat. 2014 May;21 Suppl 1:60-89. doi: 10.1111/jvh.12249.

PMID:
24713006
29.

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm.

Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, Vogel W, Mendes Correa MC, Hézode C, Lázaro P, Akarca U, Aleman S, Balık I, Berg T, Bihl F, Bilodeau M, Blasco AJ, Brandão Mello CE, Bruggmann P, Buti M, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cramp ME, Dore GJ, Doss W, Duberg AS, El-Sayed MH, Ergör G, Esmat G, Falconer K, Félix J, Ferraz ML, Ferreira PR, Frankova S, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL Jr, Gower E, Gschwantler M, Guimarães Pessôa M, Hindman SJ, Hofer H, Husa P, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Marinho RT, Marotta P, Mauss S, Moreno C, Murphy K, Negro F, Nemecek V, Örmeci N, Øvrehus AL, Parkes J, Pasini K, Peltekian KM, Ramji A, Reis N, Roberts SK, Rosenberg WM, Roudot-Thoraval F, Ryder SD, Sarmento-Castro R, Semela D, Sherman M, Shiha GE, Sievert W, Sperl J, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, Van Damme P, van Thiel I, Van Vlierberghe H, Vandijck D, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Cornberg M, Müllhaupt B, Estes C.

J Viral Hepat. 2014 May;21 Suppl 1:34-59. doi: 10.1111/jvh.12248.

PMID:
24713005
30.

Historical epidemiology of hepatitis C virus (HCV) in selected countries.

Bruggmann P, Berg T, Øvrehus AL, Moreno C, Brandão Mello CE, Roudot-Thoraval F, Marinho RT, Sherman M, Ryder SD, Sperl J, Akarca U, Balık I, Bihl F, Bilodeau M, Blasco AJ, Buti M, Calinas F, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cornberg M, Cramp ME, Dore GJ, Doss W, Duberg AS, El-Sayed MH, Ergör G, Esmat G, Estes C, Falconer K, Félix J, Ferraz ML, Ferreira PR, Frankova S, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL Jr, Gower E, Gschwantler M, Guimarães Pessôa M, Hézode C, Hofer H, Husa P, Idilman R, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Lázaro P, Marotta P, Mauss S, Mendes Correa MC, Müllhaupt B, Myers RP, Negro F, Nemecek V, Örmeci N, Parkes J, Peltekian KM, Ramji A, Razavi H, Reis N, Roberts SK, Rosenberg WM, Sarmento-Castro R, Sarrazin C, Semela D, Shiha GE, Sievert W, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, van Thiel I, Van Vlierberghe H, Vandijck D, Vogel W, Waked I, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Van Damme P, Aleman S, Hindman SJ.

J Viral Hepat. 2014 May;21 Suppl 1:5-33. doi: 10.1111/jvh.12247. Review.

PMID:
24713004
31.

A randomized controlled trial assessing the effect of prescribed patient position changes during colonoscope withdrawal on adenoma detection.

Ou G, Kim E, Lakzadeh P, Tong J, Enns R, Ramji A, Whittaker S, Ko HH, Bressler B, Halparin L, Lam E, Amar J, Telford J.

Gastrointest Endosc. 2014 Aug;80(2):277-83. doi: 10.1016/j.gie.2014.01.032. Epub 2014 Mar 12.

PMID:
24629419
32.

Chronic hepatitis C in Western Canada: a survey of practice patterns among gastroenterologists in Alberta and British Columbia.

Pai R, Ramji A, Lee SS, Wong WW, Yoshida EM.

Can J Gastroenterol Hepatol. 2014 Jan;28(1):e1-4. Epub 2013 Nov 8.

33.

JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients.

Pockros PJ, Jensen D, Tsai N, Taylor R, Ramji A, Cooper C, Dickson R, Tice A, Kulkarni R, Vierling JM, Lou Munson M, Chen YC, Najera I, Thommes J; JUMP-C Investigators.

Hepatology. 2013 Aug;58(2):514-23. doi: 10.1002/hep.26275. Epub 2013 Jun 24.

PMID:
23359491
34.

An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.

Myers RP, Ramji A, Bilodeau M, Wong S, Feld JJ.

Can J Gastroenterol. 2012 Jun;26(6):359-75.

35.

Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3.

Lee SS, Sherman M, Ramji A, Greenbloom S, Elkashab M, Pluta H, Hilzenrat N, Balshaw R, Usaty C, Myers RP.

Aliment Pharmacol Ther. 2012 Jan;35(1):37-47. doi: 10.1111/j.1365-2036.2011.04911.x. Epub 2011 Nov 2.

36.

Add-on cases in the endoscopy unit: Factors that affect volume.

Segal B, Lam E, Amar J, Bressler B, Halparin L, Ramji A, Telford J, Whittaker S, Enns R.

Can J Gastroenterol. 2009 Jul;23(7):485-8.

37.

Inhibition of TRPP3 channel by amiloride and analogs.

Dai XQ, Ramji A, Liu Y, Li Q, Karpinski E, Chen XZ.

Mol Pharmacol. 2007 Dec;72(6):1576-85. Epub 2007 Sep 5.

PMID:
17804601
38.

Cadaveric ultrasound imaging for training in ultrasound-guided peripheral nerve blocks: lower extremity.

Tsui BC, Dillane D, Pillay J, Ramji AK, Walji AH.

Can J Anaesth. 2007 Jun;54(6):475-80. No abstract available.

PMID:
17541078
39.

Acute management and secondary prophylaxis of esophageal variceal bleeding: a western Canadian survey.

Cheung J, Wong W, Zandieh I, Leung Y, Lee SS, Ramji A, Yoshida EM.

Can J Gastroenterol. 2006 Aug;20(8):531-4.

40.

Predictors of employment after liver transplantation.

Sahota A, Zaghla H, Adkins R, Ramji A, Lewis S, Moser J, Sher LS, Fong TL.

Clin Transplant. 2006 Jul-Aug;20(4):490-5.

PMID:
16842527
41.

Liver transplant candidacy unsuitability: a review of the British Columbia experience.

Alali J, Ramji A, Ho JK, Scudamore CH, Erb SR, Cheung E, Kopit B, Bannon CA, Chung SW, Soos JG, Buczkowski AK, Brooks EM, Steinbrecher UP, Yoshida EM.

Can J Gastroenterol. 2006 Feb;20(2):95-9.

42.

Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus.

Chatur N, Ramji A, Bain VG, Ma MM, Marotta PJ, Ghent CN, Lilly LB, Heathcote EJ, Deschenes M, Lee SS, Steinbrecher UP, Yoshida EM.

Liver Int. 2005 Aug;25(4):723-7.

PMID:
15998421
43.

When to treat patients with chronic hepatitis C.

Heathcote J, Ramji A.

Curr Gastroenterol Rep. 2004 Aug;6(4):261-3. Review. No abstract available.

PMID:
15245691
44.

Regression of cirrhosis associated with hepatitis B e (HBe) antigen-negative chronic hepatitis B infection with prolonged lamivudine therapy.

Yoshida EM, Ramji A, Chatur N, Davis JE, Owen DA.

Eur J Gastroenterol Hepatol. 2004 Mar;16(3):355-8.

PMID:
15195902
45.

Abdominal pain as the initial and sole clinical presenting feature of systemic lupus erythematosus.

Chung HV, Ramji A, Davis JE, Chang S, Reid GD, Salh B, Freeman HJ, Yoshida EM.

Can J Gastroenterol. 2003 Feb;17(2):111-3.

PMID:
12605248
46.

Late acute rejection after liver transplantation: the Western Canada experience.

Ramji A, Yoshida EM, Bain VG, Kneteman NM, Scudamore CH, Ma MM, Steinbrecher UP, Gutfreund KS, Erb SR, Partovi N, Chung SW, Shapiro J, Wong WW.

Liver Transpl. 2002 Oct;8(10):945-51.

47.

Post-liver transplantation diabetes mellitus: an association with hepatitis C.

AlDosary AA, Ramji AS, Elliott TG, Sirrs SM, Thompson DM, Erb SR, Steinbrecher UP, Yoshida EM.

Liver Transpl. 2002 Apr;8(4):356-61.

48.

Post-liver transplant Crohn's disease: graft tolerance but not self-tolerance?

Ramji A, Owen DA, Erb SR, Scudamore CH, Yoshida EM.

Dig Dis Sci. 2002 Mar;47(3):522-7.

PMID:
11911336
49.

Diabetes mellitus after liver transplantation: another extrahepatic manifestation of hepatitis C.

Ramji A, Yoshida EM.

Can J Gastroenterol. 2001 Jul;15(7):432. No abstract available.

PMID:
11493946
50.

De novo acute hepatitis B infection in a previously vaccinated liver transplant recipient due to a strain of HBV with a Met 133 Thr mutation in the "a" determinant.

Yoshida EM, Ramji A, Erb SR, Davis JE, Steinbrecher UP, Sherlock CH, Scudamore CH, Chung SW, Williams M, Gutfreund KS.

Liver. 2000 Oct;20(5):411-4.

PMID:
11092260

Supplemental Content

Support Center